Pilot screening programme for small mole
β
Rachel G. Berkson; Jonathan J. Hollick; Nicholas J. Westwood; Julie A. Woods; Da
π
Article
π
2005
π
John Wiley and Sons
π
French
β 328 KB
## Abstract Activation of the p53 tumour suppressor is predicted to have therapeutically beneficial effects. Many current antiβcancer therapies activate the p53 response __via__ DNA damage. Nonβgenotoxic activation of the p53 pathway would open the way to longβterm and possibly prophylactic treatme